These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

186 related items for PubMed ID: 10583027

  • 1. Ketoconazole inhibits the metabolism of tolterodine in subjects with deficient CYP2D6 activity.
    Brynne N, Forslund C, Hallén B, Gustafsson LL, Bertilsson L.
    Br J Clin Pharmacol; 1999 Oct; 48(4):564-72. PubMed ID: 10583027
    [Abstract] [Full Text] [Related]

  • 2. Fluoxetine inhibits the metabolism of tolterodine-pharmacokinetic implications and proposed clinical relevance.
    Brynne N, Svanström C, Aberg-Wistedt A, Hallén B, Bertilsson L.
    Br J Clin Pharmacol; 1999 Oct; 48(4):553-63. PubMed ID: 10583026
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparison of pharmacokinetic variability of fesoterodine vs. tolterodine extended release in cytochrome P450 2D6 extensive and poor metabolizers.
    Malhotra B, Darsey E, Crownover P, Fang J, Glue P.
    Br J Clin Pharmacol; 2011 Aug; 72(2):226-34. PubMed ID: 21352267
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Food increases the bioavailability of tolterodine but not effective exposure.
    Olsson B, Brynne N, Johansson C, Arnberg H.
    J Clin Pharmacol; 2001 Mar; 41(3):298-304. PubMed ID: 11269570
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [An example of interactions between SSRI preparations and tolterodine?].
    von Segebaden C.
    Lakartidningen; 2001 May 02; 98(18):2234. PubMed ID: 11402608
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The pharmacokinetic profile of fesoterodine: similarities and differences to tolterodine.
    Simon HU, Malhotra B.
    Swiss Med Wkly; 2009 Mar 07; 139(9-10):146-51. PubMed ID: 19145494
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study.
    Rentzhog L, Stanton SL, Cardozo L, Nelson E, Fall M, Abrams P.
    Br J Urol; 1998 Jan 07; 81(1):42-8. PubMed ID: 9467475
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Thorough QT study with recommended and supratherapeutic doses of tolterodine.
    Malhotra BK, Glue P, Sweeney K, Anziano R, Mancuso J, Wicker P.
    Clin Pharmacol Ther; 2007 Mar 07; 81(3):377-85. PubMed ID: 17339867
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Food does not influence the pharmacokinetics of a new extended release formulation of tolterodine for once daily treatment of patients with overactive bladder.
    Olsson B, Szamosi J.
    Clin Pharmacokinet; 2001 Mar 07; 40(2):135-43. PubMed ID: 11286323
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.